TY - JOUR T1 - ERS International Congress 2022: highlights from the Paediatric Assembly JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00653-2022 SP - 00653-2022 AU - Cristina Ardura-Garcia AU - Katharina Kainz AU - Maria Christina Mallet AU - Laura Petrarca AU - Jasna Rodman Berlot AU - Monique Slaats AU - Carmen Streibel AU - Susanne Vijverberg AU - Emma E Williams AU - Myrofora Goutaki AU - Diane M Gray AU - Anna Lavizzari AU - Rory E. Morty AU - Marijke Proesmans AU - Dirk Schramm AU - Mirjam Stahl AU - Angela Zacharasiewicz AU - Alexander Moeller AU - Mariëlle W. Pijnenburg Y1 - 2023/01/01 UR - http://openres.ersjournals.com/content/early/2023/02/09/23120541.00653-2022.abstract N2 - This review has been prepared by the Early Career Members and Chairs of the European Respiratory Society (ERS) Assembly 7: Paediatrics. We here summarise the highlights of the advances in paediatric respiratory research presented at the ERS International Congress 2022. The eight scientific Groups of this Assembly cover a wide range of research areas, including respiratory physiology and sleep, asthma and allergy, cystic fibrosis (CF), respiratory infection and immunology, neonatology and intensive care, respiratory epidemiology, bronchology, and lung and airway developmental biology. Specifically, we report on abstracts presented at the congress on the effect of high altitude on sleep, sleep disorders, the hypoxic challenge test, and measurements of ventilation inhomogeneity. We discuss prevention of preschool wheeze and asthma, and new asthma medications. In children with CF, we describe how to monitor the effect of CF transmembrane conductance regulator modulator therapy. We present respiratory manifestations and chronic lung disease associated with common variable immunodeficiency. Furthermore, we discuss how to monitor respiratory function in neonatal and paediatric intensive care units. In respiratory epidemiology, we present the latest news from population-based and clinical cohort studies. We also focus on innovative and interventional procedures for the paediatric airway, such as cryotherapy. Finally, we stress the importance of better understanding the molecular mechanisms underlying normal and abnormal lung development.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: CAG received support from the ERS for attending meetings and was the Early Career Member Representative of the Paediatrics Assembly of the ERS.Conflict of interest: AM has received a research grant, consulting fees and honoraria for lectures from Vertex to his institution, he is Co-President of Swiss Working Group for Cystic Fibrosis and secretary of the ERS Paediatric Assembly.Conflict of interest: AZ has received payment or honoraria from Sanofi, Vertex, Astra Zeneca, Novartis Löwenstein and Hagleitner, support for attending meetings and/or travel from Gilead AOP, has participated on advisory boards from Chiesi and Vertex, and is the Head of Pediatric Asthma and Allergy Group of the Austrian Pediatric Society and of the Austrian Respiratory Society.Conflict of interest: DG has received a research fellowship from the Wellcome Trust, is an Executive Committee member of Pan African Thoracic Society, treasurer and the Co-chair of the Department of Paediatrics and Child Health Advocacy Committee, University of Cape Town.Conflict of interest: MSahl has received a payment to institution from Vertex Pharmaceuticals, has participated on a Data Safety Monitoring Board or Advisory Board for Vertex Pharmaceuticals, and is the FGM Chairwoman, GPP treasurer and secretary of group 07.03 of the ERS.Conflict of interest: MCM is supported by the Swiss National Science Foundation (320030_182628). MG is chair of the Group 07.06 of the ERS and she is supported by the Swiss National Science Foundation (PZ00P3_185923). MPijnenburg's institution received payments from Sanofi (advisory board), Novartis and AbbVie (speakers fees), she received support from the ERS for attending meetings as head of the Paediatric Assembly. MProesmans is member of the ERS Clinical Research Collaboration on non CF bronchiectasis in children (unpaid).Conflict of interest: SV is supported by the Lung Foundations Netherlands and ZonMW (payments made to institution as research funding).Conflict of interest: CS, DS, EW, JRB, KK, LP, MSlaats have nothing to disclose. ER -